Omnitrope5 mg/1.5 ml

Omnitrope is a recombinant human growth hormone (rhGH) biosynthetically identical in sequence to endogenous pituitary growth hormone. It is indicated for the following, classified by strength of evidence:

Established / Approved Pediatric Indications

• Growth hormone deficiency (GHD) in children due to inadequate endogenous growth hormone secretion.
• Turner syndrome – short stature associated with this condition, confirmed by chromosomal analysis.
• Prader-Willi syndrome (PWS) – to improve growth and body composition, confirmed by genetic testing.
• Small for gestational age (SGA) – children born small for gestational age who fail to show catch-up growth by 2 years of age.
• Growth failure due to chronic kidney disease (CKD) – used up to the time of renal transplantation, in specific approved products.
• Idiopathic short stature (ISS)/Noonan syndrome-associated short stature – in selected products, where height is significantly below normal and no other cause is identified.
• SHOX gene deficiency – short stature due to short stature homeobox-containing gene deficiency (product-specific approval).

Established / Approved Adult Indications

• Adult growth hormone deficiency (AGHD) – either childhood-onset GHD confirmed in adulthood, or adult-onset GHD due to pituitary/hypothalamic disease, pituitary surgery, radiation therapy, or head trauma, confirmed by appropriate biochemical (stimulation) testing.

Other Recognized Use (Product-Specific / Guideline-Supported)

• HIV-associated wasting/cachexia – to increase lean body mass, for specific approved formulations, as an adjunct to overall management, not a substitute for antiretroviral therapy.

Omnitrope is not approved for anti-aging use, athletic performance enhancement, bodybuilding, or growth promotion in children with normal, closed growth plates, and such use is inappropriate and unsafe.

Each vial, cartridge, or pre-filled pen of Somatropin contains synthetic human growth hormone produced by recombinant DNA technology, structurally identical (191 amino acid sequence) to human pituitary-derived growth hormone. Strength is expressed in milligrams equivalent to international units (approximately 1 mg ≈ 3 IU), commonly available as 5 mg, 5.3 mg, 6 mg, 10 mg, or 12 mg per vial/cartridge, depending on the brand and presentation.

Common excipients include glycine, mannitol, sodium phosphate buffer, poloxamer 188, and (in multi-dose liquid presentations) a preservative such as phenol or m-cresol; lyophilized (powder) presentations are supplied with a separate diluent for reconstitution.

Omnitrope is the biosynthetic (recombinant) form of human growth hormone (somatotropin), produced using recombinant DNA technology in bacterial (E. coli) or mammalian cell expression systems. It has the same 191-amino-acid sequence and biological activity as growth hormone secreted naturally by the anterior pituitary gland.

Omnitrope is used as replacement or supplemental therapy in children and adults who cannot produce sufficient natural growth hormone, or in certain genetic and growth-failure syndromes where growth hormone therapy has been shown to improve linear growth, body composition, and metabolic parameters. It is administered by subcutaneous injection and requires ongoing supervision by a physician, typically an endocrinologist.

Pituitary hormone; Recombinant human growth hormone (rhGH) analog. Omnitrope belongs to the growth hormone / somatotropin class of biologic therapeutic proteins.

Mechanism of Action

Somatropin binds to the growth hormone receptor (GHR) on the surface of target cells (primarily hepatocytes, chondrocytes, and adipocytes), inducing receptor dimerization and activation of the JAK2–STAT5 intracellular signaling pathway. This stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1), which is the principal mediator of Somatropin's growth-promoting effects on cartilage and bone (linear growth in children).

Somatropin also has direct metabolic actions: it stimulates protein synthesis and nitrogen retention (anabolic effect), promotes lipolysis and reduces fat mass, and exerts an anti-insulin (diabetogenic) effect that can increase blood glucose, particularly at higher doses.

Pharmacokinetics

Following subcutaneous injection, Somatropin is absorbed with an absolute bioavailability of approximately 70–90%; peak serum concentrations occur roughly 3–6 hours after dosing. It is metabolized primarily in the liver and kidney, with an elimination half-life of approximately 2–4 hours after subcutaneous administration (longer than after intravenous dosing due to slow absorption from the injection site).

Omnitrope is administered by subcutaneous injection only, using a fine needle, pen injector device, or needle-free injector as prescribed. Practical points:

• Inject into subcutaneous tissue of the abdomen, thigh, or buttock; rotate the injection site with each dose to reduce the risk of lipoatrophy (localized loss of fat tissue) and lipohypertrophy.
• Reconstituted or liquid solutions should be inspected visually before use; do not use if the solution is cloudy, discolored, or contains particles (see Reconstitution).
• Injections are typically given once daily; for growth-promoting indications, evening dosing is commonly recommended to mimic natural nocturnal growth hormone secretion patterns, though the physician's specific instructions should be followed.
• Patients and caregivers should be trained in proper injection technique, storage, and sharps disposal by a healthcare professional before self-administering at home.
• Do not share pens, cartridges, or needles between patients, even if the needle is changed.

Clinically significant interactions with Omnitrope include:

Adverse effects of Omnitrope vary by age group and indication.

Less Common but Clinically Important

• Benign intracranial hypertension (headache, visual changes, papilledema, nausea/vomiting)
• Hyperglycemia/new-onset or worsened diabetes mellitus
• Hypothyroidism (unmasking of latent disease)
• Slipped capital femoral epiphysis and progression of scoliosis in growing children
• Hypersensitivity reactions, including rare anaphylaxis and angioedema
• Rare reports of second neoplasm (e.g., meningioma) in childhood cancer survivors previously treated with radiation

Patients should seek prompt medical advice for severe headache with vision changes, persistent limping or hip/knee pain, signs of allergic reaction, or unusual swelling.

Pregnancy: Data on the use of Omnitrope in pregnant women are limited. Animal reproduction studies at doses several-fold higher than the human dose have not shown clear evidence of fetal harm, but adequate and well-controlled human studies are lacking. Omnitrope should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; it is generally recommended to discontinue growth hormone therapy once pregnancy is confirmed, unless a specialist advises otherwise. Always consult a physician before use during pregnancy.

Lactation: It is not known whether Omnitrope is excreted in human breast milk in clinically significant amounts; because it is a large protein molecule, systemic absorption by a breastfed infant from milk is expected to be minimal, but data are limited. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for Omnitrope therapy, in consultation with a physician.

Omnitrope should be prescribed and monitored only by a physician experienced in the diagnosis and management of growth hormone disorders (typically an endocrinologist), with regular follow-up including growth velocity (children), IGF-1 levels, glucose tolerance, and thyroid function.

• Neoplasm risk: Use with caution in patients with a history of cancer, particularly childhood cancer survivors treated with radiation, who have an increased risk of a second neoplasm (e.g., meningioma); monitor for new or recurrent malignancy.
• Glucose intolerance: Omnitrope can reduce insulin sensitivity; monitor blood glucose periodically, especially in patients with diabetes, prediabetes, obesity, or other risk factors, and adjust antidiabetic therapy as needed.
• Intracranial hypertension: Discontinue Omnitrope and evaluate promptly if papilledema, headache, nausea/vomiting, or visual changes develop; therapy may be resumed cautiously if symptoms resolve, with close monitoring for recurrence.
• Hypoadrenalism: Omnitrope can unmask central adrenal insufficiency; monitor cortisol status and adjust glucocorticoid replacement if needed (see Interactions).
• Hypothyroidism: Monitor thyroid function; untreated hypothyroidism may blunt response to Omnitrope therapy.
• Slipped capital femoral epiphysis and scoliosis: Evaluate any child who develops a limp, or hip/knee pain during treatment; monitor for progression of scoliosis in susceptible children.
• Prader-Willi syndrome: Evaluate for signs of upper airway obstruction and sleep apnea before starting and periodically during treatment; discontinue if these develop (see Contraindications). Weight management is essential.
• Injection site reactions/lipoatrophy: Rotate injection sites with every dose.
• Fluid retention: Edema, arthralgia, and carpal tunnel syndrome are common, usually mild, dose-related, and reversible on dose reduction, particularly in adults.
• Not for non-approved use: Omnitrope must not be used to enhance athletic performance, for bodybuilding, for anti-aging purposes, or for growth enhancement in children without a diagnosed, medically confirmed indication.

Acute overdose of Omnitrope may initially cause hypoglycemia (low blood sugar), followed later by hyperglycemia and fluid retention. Chronic excessive dosing can lead to signs and symptoms consistent with acromegaly/gigantism (e.g., coarsening of facial features, enlargement of hands and feet, joint pain).

If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home without medical guidance; monitoring of blood glucose and clinical status by a physician is required.

Store in a refrigerator at 2–8°C (36–46°F); do not freeze. Protect from light. Once reconstituted or if the presentation is supplied as a ready-to-use liquid pen/cartridge, follow the specific in-use storage duration and temperature stated on the product label (commonly refrigerated, and used within the stated number of days after first use). Keep Omnitrope out of reach of children. Do not use if the solution is cloudy, discolored, or contains particles.

• Renal impairment: Omnitrope is specifically indicated for growth failure associated with chronic kidney disease in children (in approved products); in adults with renal impairment, use with caution and closer monitoring, guided by clinical response.
• Hepatic impairment: No well-established dose-adjustment guidelines exist; use cautiously with specialist supervision.
• Elderly: More sensitive to the effects of Omnitrope; a lower starting dose and smaller dose increments are recommended (see Dosage).
• Pregnancy and lactation: See Pregnancy and Lactation section.
• Pediatric patients: See Pediatric Uses section.
• Obese patients: May require lower starting doses due to increased sensitivity; monitor closely for glucose intolerance.

Duration of Omnitrope therapy is individualized and determined by the treating physician. In children treated for growth-promoting indications, therapy is generally continued until near-adult height is achieved or growth plates (epiphyses) have fused, at which point further growth-promoting benefit is not expected. In adults with growth hormone deficiency, therapy is typically long-term/lifelong, continued as long as clinical benefit is demonstrated (improved body composition, quality of life, and normalized IGF-1), with periodic reassessment and possible temporary discontinuation for retesting. Treatment should never be stopped or adjusted without medical advice.

Some Omnitrope presentations are supplied as a lyophilized (freeze-dried) powder that must be reconstituted with the accompanying diluent before injection; other presentations (e.g., certain pre-filled liquid pens/cartridges) are ready to use and do not require reconstitution. For powder presentations requiring reconstitution:

• Use only the diluent supplied with the specific product; do not substitute another diluent.
• Inject the diluent slowly down the side of the vial and swirl gently to dissolve the powder; do not shake vigorously, as this may denature the protein.
• The reconstituted solution should be clear and colorless (or as specified by the product label); do not use if cloudy, discolored, or containing visible particles.
• Once reconstituted, store as directed on the specific product label (typically refrigerated at 2–8°C) and use within the stated in-use period (commonly within 14–28 days, depending on the product) — never longer than instructed.
• Always follow the reconstitution instructions provided in the specific product's package insert, as steps and in-use periods vary between brands.

Growth hormones; Recombinant human growth hormone (rhGH) analogs; Pituitary/hypothalamic hormone class. Somatropin is a biologic (protein-based) therapeutic, not a small-molecule drug.

Somatropin binds to the growth hormone receptor (GHR) expressed on hepatocytes, chondrocytes, adipocytes, and other tissues, causing receptor dimerization and activation of the intracellular JAK2/STAT5 signaling cascade. This drives hepatic and local production of insulin-like growth factor-1 (IGF-1), the key downstream mediator that stimulates chondrocyte proliferation at the epiphyseal growth plate (linear bone growth in children) and exerts anabolic effects on muscle and other tissues. Somatropin also acts directly to increase lipolysis (fat breakdown), promote nitrogen retention and protein synthesis, and reduce peripheral insulin sensitivity.

C

Omnitrope is approved for use in children for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small for gestational age without catch-up growth, chronic kidney disease-associated growth failure, and idiopathic short stature/SHOX deficiency/Noonan syndrome (approval varies by specific product). Dosing is weight-based and individualized per indication (see Dosage); safety and efficacy in children below the specific age ranges studied for each indication (as defined in the respective product labeling) have not been established, and treatment should only be initiated after appropriate diagnostic confirmation by a pediatric endocrinologist.

Children on Omnitrope require regular monitoring of growth velocity, IGF-1 levels, thyroid function, glucose tolerance, and (in Prader-Willi syndrome) screening for upper airway obstruction/sleep apnea. Any new limp, hip or knee pain, or worsening spinal curvature during treatment should be evaluated promptly for slipped capital femoral epiphysis or scoliosis progression. Omnitrope should not be used in children with closed epiphyses for growth-promotion purposes, or for cosmetic/non-diagnosed short stature.